Bayer is withdrawing the cholesterol-lowering drug Lipobay – how long ago was it?
The background
On August 8, 2001, Bayer withdrew its cholesterol-lowering drug Lipobay with the active ingredient cerivastatin from the market in many countries. Reports of severe muscle damage and even fatal outcomes had increased safety concerns. Taking the blood lipid-lowering drug gemfibrozil at the same time was particularly risky. The withdrawal became a serious crisis for the German pharmaceutical company. The case also showed why the monitoring of a drug must continue after approval: rare side effects and dangerous interactions sometimes only become apparent when they are widely used. However, the withdrawal did not affect all statins. Other agents in this group remained important drugs for lowering elevated blood lipids and reducing the risk of heart attacks.